- Home
- ANAB vs GLAD Comparison
ANAB vs GLAD Comparison
Compare ANAB & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GLAD
- Stock Information
- Founded
- ANAB 2005
- GLAD 2001
- Country
- ANAB United States
- GLAD United States
- Employees
- ANAB N/A
- GLAD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GLAD Finance/Investors Services
- Sector
- ANAB Health Care
- GLAD Finance
- Exchange
- ANAB Nasdaq
- GLAD Nasdaq
- Market Cap
- ANAB 630.2M
- GLAD 612.5M
- IPO Year
- ANAB 2017
- GLAD N/A
- Fundamental
- Price
- ANAB $21.90
- GLAD $26.05
- Analyst Decision
- ANAB Buy
- GLAD Hold
- Analyst Count
- ANAB 10
- GLAD 3
- Target Price
- ANAB $48.00
- GLAD $24.83
- AVG Volume (30 Days)
- ANAB 465.1K
- GLAD 94.9K
- Earning Date
- ANAB 11-04-2025
- GLAD 08-04-2025
- Dividend Yield
- ANAB N/A
- GLAD 7.60%
- EPS Growth
- ANAB N/A
- GLAD N/A
- EPS
- ANAB N/A
- GLAD 3.38
- Revenue
- ANAB $123,164,000.00
- GLAD $88,900,000.00
- Revenue This Year
- ANAB $11.22
- GLAD N/A
- Revenue Next Year
- ANAB $8.35
- GLAD $13.91
- P/E Ratio
- ANAB N/A
- GLAD $7.71
- Revenue Growth
- ANAB 304.17
- GLAD N/A
- 52 Week Low
- ANAB $12.21
- GLAD $21.96
- 52 Week High
- ANAB $40.70
- GLAD $30.43
- Technical
- Relative Strength Index (RSI)
- ANAB 52.43
- GLAD 35.75
- Support Level
- ANAB $19.86
- GLAD $26.06
- Resistance Level
- ANAB $22.98
- GLAD $26.60
- Average True Range (ATR)
- ANAB 1.00
- GLAD 0.37
- MACD
- ANAB 0.35
- GLAD -0.03
- Stochastic Oscillator
- ANAB 69.14
- GLAD 10.57
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.